Jimmy Weterings
Vice President, Head Oligonucleotide Therapeutics Bonito Biosciences Inc.
Jimmy Weterings is Vice President and Head of Oligonucleotide Therapeutics at Bonito Biosciences, where he leads oligonucleotide chemistry and biology efforts focused on targeted delivery. He brings more than 20 years of experience in oligonucleotide therapeutics, having worked across biotech and pharmaceutical organizations including Sirnaomics, AstraZeneca, Cristal Therapeutics, and Cenix BioScience. His work has focused on advancing oligonucleotide discovery, conjugation and delivery technologies, and he is a frequent speaker and advisor within the nucleic acid therapeutics community.
Seminars
Thursday 28th January 2027
Comparing Antibodies & Small Molecules to Best Address Immunogenicity, Biodistribution & Efficacy in Drug Development
12:00 pm
- Comparing the molecular and pharmacological properties of antibodies and small molecules to understand how size, affinity, valency and molecular architecture influence target engagement and therapeutic performance
- Exploring how modality choice impacts biodistribution, tissue penetration, dosing and productive intracellular delivery, while considering modality-specific challenges including immunogenicity and off-target exposure
- Using preclinical and clinical examples to define where antibodies and small molecules offer distinct advantages, providing a practical framework for selecting the right targeting modality for the target, tissue and therapeutic payload
